Peptides are everywhere. Wellness spas. Massage parlors. Chiropractor offices. Even rehab clinics in the US and UK now offer peptide injections.
Proponents swear they cure everything. They claim peptides combat aging. Heal injuries. Dampen inflammation. Accelerate weight loss. Treat osteoporosis. Even opioid withdrawal.
The list is endless.
The evidence? Nonexistent.
Yet people keep buying. The unregulated peptide market is estimated between $100 million and $3 billion. It is a frenzy.
“Because there’s no regulation, it is like a free-for-all,” Alexander Weber, from the University of Southern California, says. “It is like the Wild West right now.”
That chaos likely fueled a shocking move by a US Food and Drug Administration advisory committee. In a series of close votes, the group recommended lifting regulations on several experimental peptides. This would let specific pharmacies manufacture them. It would allow doctors to prescribe them.
On one hand, it reduces the risk of buying from shady online sources. On the other, it signals safety. It suggests effectiveness. Both are false.
“What this announcement did, if anything, is increase the visibility of the peptide world,” Changhan David Lee adds.
Once fringe, peptides are now mainstream. And without rigorous testing, they could cause unintended harm.
How did we get here?
Interest dates back to the 1920. Insulin became the first commercial peptide drug. But peptides are tiny. Hard to identify. Hard to characterize.
Most researchers define them as having fewer than 20 amino acids—the building blocks of proteins. The FDA sets the limit at 40. Compare that to average human proteins, which contain 400 to 50.
Technology changed everything. About 25 years ago, genetic sequencing improved. Analyzing peptides became easier. It opened a biological frontier.
Since 2000, nearly 2.3 million papers on peptides have been published. Double the 20th-century total. The FDA has approved over 40 peptide drugs in the last decade. Semaglutide stands out. It is the key ingredient in Ozempic and Wegovy. These medications transformed obesity and type 2 diabetes treatment.
“We were a big step in the peptide space.” They also propelled peptides into the public eye.
The Regulatory Grey Zone
Now, online retailers ship peptides to homes across the US, UK, Canada, and EU. But most are not approved drugs. They are experimental. Meant for research only.
Weber notes this creates a regulatory gray area. The FDA has not deemed them safe or effective. Doctors cannot prescribe them as medicine. But they can still be sold. As long as suppliers make no health claims. It is like the vitamin supplement industry. The UK and EU face similar loopholes.
Here is the danger: contamination.
“When substances are not regulated by the FDA, those companies might put, knowingly or unknowingly, whatever they want in that bottle,” Weber says.
A New Yorker article in April revealed issues. Some online peptides contained lead. Signs of bacterial contamination. Doses significantly lower than advertised.
These risks likely justified the FDA committee’s decision. They recommended adding six experimental peptides to the compounding list:
* BPC-157
* KPV
* TB-500
* MOTs-C
* Semax
* Epitalon
Emideltide was the only rejection.
Compounded products are made-to-order at select pharmacies. Usually due to shortages or allergies. The recommendations passed by slim majorities.
Controversy swirled before the vote. The week prior, the Department of Health and Human Services nominated eight new members. Six had ties to the peptide industry. The HHS stated all underwent standard ethics vetting.
If the FDA accepts this, select pharmacies adhering to integrity standards can manufacture these compounds. It brings some oversight.
“We do not protect patients by pushing them into the dark,” committee member Haleem Mohammed said during the meeting. He is also the chief medical officer at Gameday Men’s Health.
But credibility is dangerous.
“Consumers will assume it is safe and effectice,” Weber warns. Even without clinical proof.
No Human Trials
Here is the hard truth: none of these peptides have been tested rigorously. There are no clinical trials. No large participant groups. No control groups. No clear efficacy metrics.
“There are no clinical trials, no clinical studies about their use in humans. Period. Full stop. End of story,” Weber says.
Instead, we rely on animal studies. Lee and his team found MOTs-C—a peptide released during exercise—regulated blood sugar in mice. Prevented obesity. Improved speed. They are now checking if it delays Alzheimer’s, heart disease, or cancer in humans.
Animal studies are far from human trials.
Side effects remain a mystery. TB-500 accelerates tissue regeneration. Helps heal wounds in animals. But that regeneration might spur cancer growth. That risk is unevaluated. Even in animals.
How do you use them? The answers are missing.
“What strength do you use? What frequency? How long to cycle on and off? Nothing is elucidated,” Weber says.
Easing manufacturing rules might accelerate research. But until then? People are treating themselves as guinea pigs.
And nobody is watching.
